Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction meeting the following criteria:~  * Newly diagnosed disease~ * Surgically resectable tumor~ * Primary esophageal tumor \< 20 cm below the incisors~ * Tumor extending ≤ 2 cm into the cardia~* Stage T2-3, N0-1, M0-1a tumor, as determined by imaging studies and biopsy~  * Documentation by endoscopic ultrasound, endoscopy, and CT scan of the chest and abdomen required~ * Any lesion suspicious for metastasis must be biopsied~ * M1a disease (i.e., celiac nodal metastasis) is allowed if other eligibility criteria are met~ * T4 disease (i.e., involvement of the pleura, pericardium, or diaphragm) allowed provided it is considered resectable~* No CNS metastasis~* ECOG performance status 0-1~* Granulocyte count \> 1,000/mm³~* Platelet count \> 75,000/mm³~* Creatinine clearance \> 60 mL/min~* Total bilirubin \< 1.5 mg/dL~* No concurrent illness likely to preclude protocol therapy or surgical resection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study therapy Exclusion Criteria~* Known severe hypersensitivity to gefitinib or any of its excipients~* Evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)~* Evidence of other significant clinical disorder or laboratory finding that would preclude study participation~* Evidence of clinically active interstitial lung disease~* Chronic, stable radiographic changes that are asymptomatic are eligible~* Prior or concurrent malignancy except basal cell or squamous cell skin cancer, cervical cancer, or any other curatively treated malignancy from which the patient has been disease-free and has a survival prognosis of \> 5 years~* Preexisting peripheral neuropathy \> grade 1~* Incomplete healing from prior oncologic or other major surgery~* Prior chemotherapy, radiotherapy, or surgery for this cancer~* More than 30 days since prior nonapproved or investigational drugs~* Concurrent phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital, or Hypericum perforatum (St. John's wort)~* Concurrent oral retinoids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Paclitaxel, Cisplatin, ZD1839 and Radiotherapy (Type: EXPERIMENTAL): Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839

Based on this trial design, predict the completion outcome and termination type (if applicable).